Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock - December 6, 2019
- Sichenzia Ross Ference Trust & Estate Attorneys Quoted in LegalZoom Article - December 6, 2019
- Sichenzia Ross Ference Represents H-Cyte, Inc. in $6.0 Million Private Placement - December 2, 2019